Early Lapatinib-Induced Skin Rash Predicts Better Survival With

Early development of skin rash following lapatinib and trastuzumab therapy is associated with improved survival.

Prognostic value of early rash in all lapatinib-containing

Efficacy and Tolerability of Lapatinib in the Management of Breast

Association between pertuzumab-associated diarrhoea and rash and

Molecular Heterogeneity and Response to Neoadjuvant Human

Development of prediction tools for diarrhea and rash in breast

Pyrotinib-based therapeutic approaches for HER2-positive breast

Evolution of Case 2-cutaneous metastasis: (A) before TDM1

Page 1597 – Cancer Therapy Advisor

Molecular Heterogeneity and Response to Neoadjuvant Human

Association between pertuzumab-associated diarrhoea and rash and

Multicenter Phase II Study of Neoadjuvant Lapatinib and

Adverse effects of tyrosine kinase inhibitors in cancer therapy

Frontiers Exceptional and Durable Responses to TDM-1 After

Recommendations on management of EGFR inhibitor-induced skin

Lapatinib as a component of neoadjuvant therapy for HER2-positive